Background {#Sec1}
==========

*Leishmania (Leishmania) infantum* is a flagellate protozoon with a heterogenic cycle that belongs to the genus *Leishmania*, which is in the family Trypanosomatidae of the order Kinetoplastida \[[@CR1]\]. This parasite is the etiological agent for visceral leishmaniasis, a zoonosis with worldwide distribution. Most of the cases are concentrated in Bangladesh, Nepal, India, South Sudan and Brazil. The development of this parasite comprises two morphological forms, whose main differences are the position of the kinetoplast in relation to the nucleus and the presence of a free flagellum associated with the undulating membrane \[[@CR2], [@CR3]\]. The promastigote form is found in arthropod vectors, represented by insects of the phlebotomine group \[[@CR4]\], while amastigote forms are found inside cells of the mononuclear phagocytic system of vertebrate hosts such as rodents, marsupials, bats, canids and humans \[[@CR5], [@CR6]\].

The severity of the disease is explained by the high virulence of its etiological agents, which results from the action of a set of functional molecules with intense biological activity in their hosts. The role of protease inhibitors in the development of pathogenic mechanisms was investigated \[[@CR7]\]. These enzymes can be divided into endopeptidases and exopeptidases, depending on the site of hydrolysis. If the residue present at the catalytic site is taken into account, they are divided into metalloproteases, serine proteases, aspartic proteases and cysteine proteases \[[@CR8]\]. In the genus *Leishmania*, cysteine proteases are the most abundant class of enzymes and are concentrated inside megasomes, where they act towards regulation of metabolic routes, cell differentiation in vertebrates and vectors, cell invasion and transposition of tissue barriers, degradation of hemoglobin and other hematopoietic proteins, evasion of the immune response, activation of inflammatory responses and programmed cell death \[[@CR9]\].

Cathepsin L-*like* cysteine proteases in *Leishmania* have three isoforms, named cysteine protease A (CPA), cysteine protease B (CPB) and cysteine protease C (CPC). These are biochemically organized into four domains (predomain, prodomain, catalytic domain, C-terminal extension) that result from expression of a multigenic family arranged in tandem. In the specific case of *L. infantum,* two isoforms are expressed, the CPB isoform expressed in the promastigote forms found in the insect vectors and the CPA isoform, in which transcriptomic studies revealed a unique expression profile of the amastigote forms \[[@CR10]\].

They are, therefore, used to construct phylogenetic inferences of close sequences and to resolve problems regarding polytomy and inferences of low support \[[@CR11], [@CR12]\]. Cathepsin genes have already been used for understanding phylogenetic relationships and as a target for making molecular diagnoses regarding other trypanosomatid species \[[@CR13]--[@CR15]\]. However, there are no studies that characterize this gene in *L. infantum* or that investigate it as a possible diagnostic marker that might help to solve recurrent problems regarding diagnostic investigation of this parasite within the clinical routine and in epidemiological investigations.

Despite the high importance of this disease, there is some difficulty in standardizing diagnostic methodologies with high predictive values for reservoir surveys. Making a direct diagnosis is invasive and laborious, and only low levels of sensitivity are reached \[[@CR16]--[@CR18]\]. The serological tests also have a series of technical limitations, such as low specificity values resulting from cross-reactions with other trypanosomatids, low concordance indices between different serological tests and lack of consensus regarding the nature and use of the antigenic product to be employed \[[@CR19]--[@CR22]\].

Thus, the objective of this study was to evaluate the CPA isoform of cathepsin L-*like* sequences as a marker for genetic analysis on intraspecific variability of *L. infantum* and as a marker for making molecular diagnoses on visceral leishmaniasis.

Methods {#Sec2}
=======

Leishmania isolates, DNA preparation, amplification and sequencing of cathepsin L-*like* gene {#Sec3}
---------------------------------------------------------------------------------------------

DNA from 44 *Leishmania* isolates (Table [1](#Tab1){ref-type="table"}) was extracted from culture supernatants using the phenol-chloroform method and from primary samples (human blood, urine, conjunctival swabs from dogs and sandfly material) in accordance with the protocol established for the Purelink kit (Thermo Fisher Scientific Inc., 2012, USA). Table 1*Leishmania infantum* isolates, host, geographical origin and sequences of Cathepsin L-*like* employed in the phylogenetic analysis performed in this studyCBT^a^HostGeographical originAccession number^b^01*Canis familiaris*SPMH42779312*Canis familiaris*RecreioRJMH42779413*Canis familiaris*MangaratibaRJMH42779514*Canis familiaris*Ilha GrandeRJMH42779615*Canis familiaris*Barra da TijucaRJMH42779716*Canis familiaris*RecreioRJMH42779817*Canis familiaris*CuiabáMTMH42779918*Canis familiaris*Ilha de GuaratibaRJMH42780020*Canis familiaris*CuiabáMTMH42780122*Canis familiaris*CaucaiaCEMH42780223*Canis familiaris*FortalezaCEMH42780324*Canis familiaris*JequiéBAMH42780425*Canis familiaris*Campo GrandeMSMH42780526*Canis familiaris*DFMH42780627*Cerdocyon thous*PAMH42780728*Canis familiaris*TeresinaPIMH42780829*Canis familiaris*TeresinaPIMH42780930*Canis familiaris*UruguaianaRSMH42781031*Canis familiaris*UruguaianaRSMH42781134*Canis familiaris*PetrolinaPEMH42781237*Canis familiaris*PetrolinaPEMH42781339*Canis familiaris*SantarémPAMH42781440*Canis familiaris*SantarémPAMH42781543*Canis familiaris*SantarémPAMH42781644*Canis familiaris*SantarémPAMH42781749*Canis familiaris*Campo GrandeMSMH42781850*Canis familiaris*Campo GrandeMSMH42781954*Canis familiaris*TeresinaPIMH42782055*Canis familiaris*TeresinaPIMH42782156*Canis familiaris*Campo GrandeMSMH42782257*Canis familiaris*Campo GrandeMSMH42782362*Canis familiaris*PetrolinaPEMH42782496*Canis familiaris*CaxiasMAMH427825105*Canis familiaris*NatalRNMH427826106*Canis familiaris*NatalRNMH427827107*Canis familiaris*NatalRNMH427828108*Canis familiaris*NatalRNMH427829124*Canis familiaris*NatalRNMH427830125*Canis familiaris*NatalRNMH427831126*Canis familiaris*NatalRNMH427832153*Canis familiaris*São DomingosMAMH427833179*Canis familiaris*PatosPBMH427834211*Homo sapiens*MaríliaSPMH427835212*Homo sapiens*MaríliaSPMH427836Brazilian states: BA, Bahia; CE, Ceará; DF, Distrito Federal; MA, Maranhão; MS, Mato Grosso do Sul; MT, Mato Grosso; PA, Pará; PB, Paraíba; PE, Pernambuco; PI, Piauí; RJ, Rio de Janeiro; RN, Rio Grande do Norte; RS, Rio Grande do Sul; SP, São Paulo^a^Coleção Brasileira de Tripanossomatídeos^b^GenBank acession number

First of all, the extracted DNA samples were quantified and submitted to conventional polymerase chain reactions (PCR) using the specific primers to Mammalian Cytochrome B as a constitutive gene, to ensure the quality of the samples \[[@CR23]\]. After this quality control, the DNA samples were submitted to the PCR reactions using high-fidelity Taq DNA polymerase with the specific primers designated for Cathepsin L-*like* CPA from *Leishmania* \[[@CR24]\] which comprised a fragment of around 893 base pairs (bp).

All the isolates were included in the Brazilian Trypanosomatid Collection (Coleção Brasileira de Tripanossomatídeos, CBT) of the School of Veterinary Medicine of the University of São Paulo, Brazil.

Phylogenetic analysis {#Sec4}
---------------------

The sequences obtained were aligned with sequences retrieved from GenBank using ClustalX \[[@CR25]\] and were adjusted manually using GeneDoc \[[@CR26]\] and then deposited in GenBank (Table [1](#Tab1){ref-type="table"}). The cathepsin L-*like* CPA sequences were used to construct a phylogenetic tree using maximum parsimony, as implemented in PAUP version 4.0b10 \[[@CR27]\] with 500 bootstrap replicates. Bayesian analysis was performed using MrBayes v3.1.2 \[[@CR28]\] with 1,000,000 replicates. The first 25% of the trees represented burn-in, and the remaining trees were used to calculate Bayesian posterior probability.

Standardization of *L. infantum*-specific assay based on cathepsin L-*like* protease {#Sec5}
------------------------------------------------------------------------------------

The aligned cathepsin L-*like* CPA gene sequences were used to search for consensus regions and to design specific primers for diagnosing *L. infantum*. The criteria used to define the primer pair were the guanine-to-cytosine ratio, formation of guanidine/cytosine (GC) staples, formation of self-homologies, self-dimer formation measured using the ΔG value, melting temperature and in silico specificity of the primers through BLASTn.

A specific PCR procedure (designated CatLeish-PCR) was developed for amplification of 223 bp of genomic DNA from *L. infantum*, using the CatLeishF primer (5′ GACAACGGCACCGTCGGCGCCAAAATAAAAG 3′) and CatLeishR primer (5′ CAGTACGGCGGTTTCGCTTGTCTGTTGAAGC 3′) (Fig. [1](#Fig1){ref-type="fig"}). The standard conditions for amplification of the cathepsin L-*like* CPA sequences comprised 34 cycles of denaturation at 94 °C for 1 min, annealing at 64 °C for 1 min and extension at 72 °C for 45 s. Fig. 1Alignment of cathepsin L-*like* CPA sequences from *Leishmania infantum*. Schematic representation of primers used for PCR amplification

Sensitivity and specificity assay on CatLeish-PCR {#Sec6}
-------------------------------------------------

For sensitivity tests, DNA from *L. infantum* was serially diluted at the concentrations of 1 × 10^− 7^, 1 × 10^− 8^, 1 × 10^− 9^, 1 × 10^− 10^, 1 × 10^− 11^, 1 × 10^− 12^, 1 × 10^− 13^, 1 × 10^− 14^ and 1 × 10^− 15^ ng/μl.

Specificity tests were performed on DNA samples from other parasite species in the genus *Leishmania*, including: *Leishmania (Viannia) braziliensis*, *Leishmania (Viannia) guyanensis*, *Leishmania (Viannia) naiffi*, *Leishmania (Leishmania) amazonensis*, *Leishmania (Leishmania) mexicana*, *Leishmania (Sauroleishmania) gymnodactyli*, *Leishmania (Sauroleishmania) adleri*, *Leishmania (Sauroleishmania) tarentolae* and *Leishmania (Mundinia) enriettii.* In addition, the following species in the genus *Trypanosoma* were tested: *Trypanosoma dionisii*, *Trypanosoma terrestris*, *Trypanosoma cruzi*, *Trypanosoma cruzi marinkellei*, *Trypanosoma theileri* and *Trypanosoma gennarii*; along with two other pathogenic species that are common in dogs: *Babesia canis* and *Ehrlichia canis*.

Application of CatLeish-PCR to clinical samples {#Sec7}
-----------------------------------------------

CatLeish-PCR was tested on a panel of clinical samples of purified DNA obtained from dogs in endemic and non-endemic regions in São Paulo state, Brazil. In addition, blood samples (prepared on filter paper), conjunctival swabs and urine samples from dogs that were known to be positive in the parasitological test were used. DNA samples obtained from human patients blood from Marília, São Paulo state and DNA extracted from sandflies caught in Bom Jesus dos Perdões, São Paulo state were also tested in pools. All samples were further tested using the ITS rDNA marker \[[@CR29]\].

Results {#Sec8}
=======

Forty-four sequences were obtained from cathepsin L-*like* CPA and they were all identical, without polymorphism, and presented 99% similarity with cysteine peptidase isoform A of *Leishmania infantum* (XM_001465076.1) from Europe. The sequences of cathepsin L-like CPA from *L. infantum* were identical and all isolates were clustered together (100% bootstrap/100% posterior probability and 100% similarity) (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Dendrogram based on 44 cathepsin L-*like* sequences from *Leishmania infantum*, which was used for making maximum parsimony and Bayesian inferences with 892 characteristics. Numbers at nodes are the support values for the major branches (bootstrap/posterior probability; 500 replicates). The sequences obtained in the present study are underlined

*Leishmania* species were aggregated in a monophyletic group (Fig. [2](#Fig2){ref-type="fig"}). The different species of the genus *Leishmania* were segregated into four groups: I. *Leishmania* species with mucocutaneous clinical manifestations, including *L. guyanensis*, *L. braziliensis* and *L. panamensis* (0.1% divergence of sequences and 100% bootstrap and 1.0 posterior probability); II. Species with cutaneous manifestations, including *L. pifanoi*, *L. mexicana* and *L. amazonensis* (0.52% divergence of sequences and 100% bootstrap and 1.0 posterior probability); III. *Leishmania* species causing cutaneous "oriental sore", including *L. major* and *L. aethiopica* (1.53% divergence of sequences and 100% bootstrap and 1.0 posterior probability); and IV. New and Old-World species of visceral leishmaniasis (0.14% divergence of sequences and 100% bootstrap and 1.0 posterior probability), separated according to the geographical origin of the isolates (Fig. [2](#Fig2){ref-type="fig"}).

The in silico analyses on the primers proposed for the specific PCR did not indicate any possibility of formation of GC staples, self-dimers and auto-homologies. The CatLeishF primer showed a GC ratio of 54.5% with an estimated melting temperature of 66.2 °C, whereas the CatLeishR primer had a GC ratio of 57.6% with a melting temperature corresponding to 65.5 °C. In BLASTn analysis, these primers were specific for *L. infantum*, with no homology containing sequences from other species deposited in the database.

CatLeish-PCR reactions with genomic DNA from *L. infantum* isolates demonstrated that there was a correct amplification, since amplicon sequencing revealed in BLASTn a percentage of 99% similarity to deposited sequences of cysteine protease genes from European strains of *L. infantum* (XM_001465076.1) and identical to American *L. infantum* sequences obtained in this study. Sensitivity measurement demonstrated that the markers were efficient at amplifying the target DNA and forming detectable bands at concentrations of up to 10^− 11^ ng/μl (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3CatLeish-PCR for diagnosis of *Leishmania infantum* based on Cathepsin L-like sequences. **a** Specificity analysis using DNA, *Leishmania* and *Trypanosoma* sequences and other hemoparasites from dogs (*Babesia* and *Ehrlichia*). **b** Sensitivity analysis using DNA from *Leishmania infantum* in different concentrations

Different species of the genus *Leishmania* were tested and there was no cross-amplification with any of the species epidemiologically associated with the cutaneous or tegumentary leishmaniasis complex in Brazil. When the molecular diagnosis was tested against hemoparasites belonging to the genera *Babesia*, *Ehrlichia* and *Trypanosoma*, there was no amplification (Fig. [3](#Fig3){ref-type="fig"}).

The use of CatLeish-PCR in the panel of clinical samples revealed that frequency of positive dogs was 49.03%, thus contrasting with the 14.42% achieved through using primers for the ribosomal ITS gene. All samples that were positive in the reactions for the ITS gene were positive in reactions for the cathepsin gene. In the human samples, 6.25% were positive, whereas in samples from sandflies, the positivity was 14.28% in pools (Table [2](#Tab2){ref-type="table"}). Table 2Positivity of naturally infected biological samples based on Cathepsin L-*like*of *Leishmania infantum* (CatLeish-PCR) markerSamples (number)Positives samples (%)CatLeish-PCRITSDogs blood (208)49,03 (102)14,42 (30)Dogs urine (3)33 (1)Dogs conjuntival swab (4)50 (2)Dogs blood in filter paper (4)100 (4)Human blood (50)6,25 (3)Sand flies (21)14,28 (3)

The samples from parasitologically positive dogs showed different rates of positivity according to the material tested. Urine samples showed 33% positivity, conjunctival swabs 50%, samples preserved on filter paper 100% and whole blood samples 100%.

The CatLeish-PCR was replicated several times during standardization with DNA samples from American *L. infantum* isolates, and subsequently technical replication was tested with clinical samples. Regardless of the samples tested, the technical replication and amplification standard were maintained (Additional file [1](#MOESM1){ref-type="media"}).

Discussion {#Sec9}
==========

The phylogenetic inferences from maximum parsimony and Bayesian analyses revealed a pattern of high similarity for *L. infantum* isolates, as observed in inferences based on SSUrDNA and gGAPDH genes \[[@CR30]\]. The segregation of *L. infantum* from Europe and America corroborates the notion that this species was introduced to the Americas during the colonization period \[[@CR30]\].

This absence of divergence, even among isolates from biomes with different climates, rainfall, vegetation cover and availability of hosts and arthropod vectors, corroborates the theory that this parasite is not autochthonous to the Americas \[[@CR31]\]. This finding indicates that the event leading to introduction of this parasite to the New World was recent. It can therefore probably be dated to the process of Ibero-American colonization that began in the fifteenth century, caused by the arrival of infected dogs and rodents \[[@CR32]\]. Focusing only on a few specific genes we can speculate that this short evolutionary time interval would be insufficient for the appearance and fixation of possible mutations in the population.

These results refute the hypothesis of a scenario in which the parasite responsible for cases of visceral leishmaniasis is native to the Americas \[[@CR30]--[@CR33]\]. Thus, the argument that the parasite is autochthonous in that it is adapted to parasitism in other wild fauna reservoirs can be countered through attributing this adaptation to the eclectic dietary habits of the vector insects \[[@CR34]\].

The phylogenetic analysis on the cathepsin L-*Like* CPA gene showed clustering that reflects the distinct clinical manifestations of *Leishmania* infection, and it was similar to amino acid analyses on cysteine proteases \[[@CR24]\]. In addition, the topology generated using the cathepsin L-*like* gene also corroborates data generated using ribosomal spacers and cytochrome B \[[@CR35], [@CR36]\].

The inferences correctly solved the differentiation of the species that are considered to be the etiological agent of tegumentary forms of the disease. One of the clades grouped *L. guyanensis*, *L. panamensis* and *L. braziliensis*, and this reflected the findings of studies in which, analyzing otorhinolaryngological conditions, most of the etiology of mucocutaneous leishmaniasis was attributed to *L. braziliensis* and *L. panamensis*, as well as results in which clinical situations of mucosal involvement were attributed to *L. guyanensis* \[[@CR37], [@CR38]\].

A second group included *L. amazonensis* and *L. mexicana*, species that have been widely associated with cutaneous manifestations of tegumentary leishmaniasis in the New World \[[@CR39]--[@CR43]\]. The *L. pifanoi* sequences were positioned in this same group. Although this species has lower epidemiological impact regarding disease transmission, it belongs to the *L. mexicana* complex \[[@CR44]\]. Therefore, this result corroborates the data demonstrating similarity among the species of this complex, with regard to proposing specific markers for kinetoplast DNA (kDNA) \[[@CR45]\].

These results confirm that the cathepsin L-*like* CPA gene is a good marker for phylogenetic positioning of species of the genus *Leishmania*, which suggests that this gene may be a good target for making the molecular diagnosis of leishmaniasis. This would enable satisfactory differentiation between the clinical forms of the disease, including among the variants of the tegumentary forms, which may aid in prescribing therapy, establishing the medical prognosis for the disease and mitigating the recurrent problems of specific diagnosis. We agree that the number of isolates collected in this work is sufficient to portray the dispersal of the parasite in Brazil.

Cathepsin gene-based assays have shown excellent results with regard to diagnosing the following *Trypanosoma* species: *T. vivax* \[[@CR13]\], *T. congolense* \[[@CR46]\], *T. theileri* \[[@CR47]\], *T. cruzi* \[[@CR48]\] and *T. rangeli* \[[@CR49]\]. However, the low numbers of copies of this gene in the genome are very specific and especially sensitive \[[@CR13]\].

Cathepsin L-*like* protease is differentially expressed in different forms of the parasite \[[@CR50], [@CR51]\]. The CPA isoform is preferentially expressed in amastigote forms. In vertebrates (both human and animal hosts), amastigotes are the replicative form and cathepsin L-*like* CPA is continuously expressed \[[@CR24]\]. The expression pattern of cathepsin L-*like* CPA and the presence of immunogenic epitopes may indicate it as an interesting target in diagnostic-serological tests, which are preferentially used in the clinical routine \[[@CR25]\].

The diagnostic marker based on the cathepsin L-*like* CPA gene has shown high sensitivity and was specific for *L. infantum*, which enables direct use in clinical samples both in non-endemic areas with imported cases and in endemic areas in which different species of *Leishmania* may be circulating. Thus, it has been proven to be effective for epidemiological surveys on human hosts, animal reservoirs and arthropod vectors. Another advantage that makes CatLeish-PCR feasible is that there is no need for complementary restriction enzyme digestion steps or use of robust high-resolution melting equipment for identifying *L. infantum*, which makes the method less costly and less cumbersome than other methodologies that are available \[[@CR52]\].

In comparison with the markers for the ITS gene, CatLeish-PCR demonstrated higher prevalence of leishmaniasis, which thus corroborated the diagnostic sensitivity of the marker. The marker was effective in making the diagnosis, both from positive swab samples from conjunctival lesions and from blood samples fixed on filter paper, reinforcing the high sensitivity of CatLeish-PCR. The positive animals in the parasitological examination were also positive when submitted to molecular diagnosis based on the cathepsin L-*like* gene, except for the urine samples given the low amount of DNA in two animals. This versatility is important because samples fixed on filter paper are easier to transport and store, given their stability, as well as exempt invasive collection methodologies \[[@CR29]\].

The diagnostic method works very well for blood samples and even though the number of samples from other sources is reduced, the method borrows our hypothesis of good molecular marker for diagnosis in biological samples with DNA. Amplification was observed even in samples extracted from urine, whose DNA concentration is considerably reduced, corresponding only to fragments of the dead parasite excreted in the urinary system \[[@CR53]\]. It should be noted that even with low levels of positivity in the assays using biological samples as a template, we still support our indication of the use of the Cathepsin gene for PCR diagnosis, since even in biological samples where the genetic material of the parasites is scarce or damaged, we obtained satisfactory amplifications. Considering this, CatLeish-PCR may have potential for monitoring the remission of infection in patients with visceral leishmaniasis and as an indicator of the efficacy of possible therapeutic approaches \[[@CR54]\].

The results presented here allow us to propose that CatLeish-PCR is a tool that can be used for diagnosing visceral leishmaniasis. It surmounts the recurrent problems of low sensitivity that direct visualization methodologies present and those of low specificity and agreement among the serological methods that have preferentially ben recommended for diagnosing this disease \[[@CR55]\]. The molecular diagnostic assays used and described in the literature have low sensitivity and specificity. Markers based on the cytochrome b gene are non-specific \[[@CR56]\]. Markers based on genes present in the kinetoplast have high sensitivity, but their specificity is low \[[@CR57], [@CR58]\]. Markers based on ribosomal genes are specific, but not very sensitive \[[@CR59]\]. Other assays such as restriction fragment length polymorphism (PCR-RFLP) have been standardized, but these raise the cost of making the diagnosis or still require sequencing of the product \[[@CR60]--[@CR62]\].

Epidemiological studies are important for recognizing active transmission cycles or introduction of parasites into new areas. Therefore, precise diagnostic methods are essential for diagnosing the presence of a parasite that is still emerging in many regions. Moreover, making a precise diagnosis minimizes the need to destroy dogs, which are the main reservoirs, given that in some countries this prophylactic measure used in combating human leishmaniasis.

Conclusion {#Sec10}
==========

This is the first work that characterizes the CPA isoform of the L-*like* cathepsin gene of *L. infantum*, demonstrating the lack of genetic variability among the Brazilian isolates of *L. infantum*. We propose that the gene studied here be an efficient phylogenetic marker for parasites of the genus *Leishmania*, and also the developed CatLeish-PCR has been shown to be sensitive and specific for the effective clinical diagnosis of this zoonosis in dogs and humans.

Supplementary information
=========================

 {#Sec11}

**Additional file 1.** Amplification patterns of CatLeish-PCR for diagnosis of *Leishmania infantum* in samples from dogs, humans and sand flies.
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